Hereditary spastic paraplegias (HSPs) comprise a group of neurodegenerative disorders that are characterized by progressive spasticity of the lower extremities, due to axonal degeneration in the corticospinal motor tracts. HSPs are genetically heterogeneous and show autosomal dominant inheritance in ~70–80% of cases, with additional cases being recessive or X-linked. The most common type of HSP is SPG4 with mutations in the SPAST gene, encoding spastin, which occurs in 40% of dominantly inherited cases and in ~10% of sporadic cases. Both loss-of-function and dominant-negative mutation mechanisms have been described for SPG4, suggesting that precise or stoichiometric levels of spastin are necessary for biological function. Therefore, we hypothesized that regulatory mechanisms controlling expression of SPAST are important determinants of spastin biology, and if altered, could contribute to the development and progression of the disease. To examine the transcriptional and post-transcriptional regulation of SPAST, we used molecular phylogenetic methods to identify conserved sequences for putative transcription factor binding sites and miRNA targeting motifs in the SPAST promoter and 3′-UTR, respectively. By a variety of molecular methods, we demonstrate that SPAST transcription is positively regulated by NRF1 and SOX11. Furthermore, we show that miR-96 and miR-182 negatively regulate SPAST by effects on mRNA stability and protein level. These transcriptional and miRNA regulatory mechanisms provide new functional targets for mutation screening and therapeutic targeting in HSP.
References
[1]
Crosby AH, Proukakis C (2002) Is the transportation highway the right road for hereditary spastic paraplegia? Am J Hum Genet 71: 1009–1016.
[2]
Depienne C, Stevanin G, Brice A, Durr A (2007) Hereditary spastic paraplegias: an update. Curr Opin Neurol 20: 674–680.
[3]
Salinas S, Proukakis C, Crosby A, Warner TT (2008) Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 7: 1127–1138.
[4]
Fink JK (2009) Hereditary spastic paraplegia overview. In GeneReviews, ed. Pagon RA, Bird TC, Dolan CR, Stephens K, University of Washington, Seattle.
[5]
Blackstone C, O’Kane CJ, Reid E (2011) Hereditary spastic paraplegias: membrane traffic and the motor pathway. Nat Rev Neurosci 12: 31–42.
[6]
Wharton SB, McDermott CJ, Grierson AJ, Wood JD, Gelsthorpe C, et al. (2003) The cellular and molecular pathology of the motor system in hereditary spastic paraparesis due to mutation of the spastin gene. J Neuropathol Exp Neurol 62: 1166–1177.
[7]
Dion PA, Daoud H, Rouleau GA (2009) Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 10: 769–782.
[8]
Depienne C, Fedirko E, Forlani S, Cazeneuve C, Riba？ P, et al. (2007) Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet 44: 281–284.
[9]
Shoukier M, Neesen J, Sauter SM, Argyriou L, Doerwald N, et al. (2009) Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. Eur J Hum Genet 17: 187–194.
[10]
Alvarez V, Sánchez-Ferrero E, Beetz C, Díaz M, Alonso B, et al. (2010) Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurol 10: 89.
[11]
de Bot ST, van den Elzen RT, Mensenkamp AR, Schelhaas HJ, Willemsen MA, et al. (2010) Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. J Neurol Neurosurg Psychiatry 81: 1073–1078.
[12]
Magariello A, Muglia M, Patitucci A, Ungaro C, Mazzei R, et al. (2010) Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. J Neurol Sci 288: 96–100.
[13]
McCorquodale DS , Ozomaro U, Huang J, Montenegro G, Kushman A, et al. (2011) Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic paraplegia. Clin Genet 79: 523–530.
[14]
Beetz C, Nygren AO, Schickel J, Auer-Grumbach M, Bürk K, et al. (2006) High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia. Neurology 67: 1926–1930.
[15]
Hansen JJ, Dürr A, Cournu-Rebeix I, Georgopoulos C, Ang D, et al. (2002) Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet 70: 1328–133.
[16]
Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, et al. (2002) A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 71: 1189–1194.
[17]
Rainier S, Chai JH, Tokarz D, Nicholls RD, Fink JK (2003) NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 73: 967–971.
[18]
Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, et al. (2004) Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 36: 271–276.
[19]
Valdmanis PN, Meijer IA, Reynolds A, Lei A, MacLeod P, et al. (2007) Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia. Am J Hum Genet 80: 152–161.
[20]
Beetz C, Schüle R, Deconinck T, Tran-Viet KN, Zhu H, et al. (2008) REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain 131: 1078–1086.
[21]
Lin P, Li J, Liu Q, Mao F, Li J, et al. (2008) A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42). Am J Hum Genet 83: 752–759.
[22]
Hazan J, Fonknechten N, Mavel D, Paternotte C, Samson D, et al. (1999) Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 23: 296–303.
[23]
Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP (2005) Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. J Cell Biol 168: 599–606.
[24]
Bürger J, Fonknechten N, Hoeltzenbein M, Neumann L, Bratanoff E, et al. (2000) Hereditary spastic paraplegia caused by mutations in the SPG4 gene. Eur J Hum Genet 8: 771–776.
[25]
Riano E, Martignoni M, Mancuso G, Cartelli D, Crippa F, et al. (2009) Pleiotropic effects of spastin on neurite growth depending on expression levels. J Neurochem 108: 1277–1288.
[26]
Pantakani DV, Swapna LS, Srinivasan N, Mannan AU (2008) Spastin oligomerizes into a hexamer and the mutant spastin (E442Q) redistribute the wild-type spastin into filamentous microtubule. J Neurochem 106: 613–624.
[27]
Solowska JM, Garbern JY, Baas PW (2010) Evaluation of loss of function as an explanation for SPG4-based hereditary spastic paraplegia. Hum Mol Genet 19: 2767–2779.
[28]
White SR, Evans KJ, Lary J, Cole JL, Lauring B (2007) Recognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severing. J Cell Biol 176: 995–1005.
[29]
Roll-Mecak A, Vale RD (2008) Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature 451: 363–367.
[30]
Lumb J, Connell J, Allison R, Reid E (2012) The AAA ATPase spastin links microtubule severing to membrane modelling. Biochim Biophys Acta. 1823: 192-197. pp. 192–197.
[31]
Mancuso G, Rugarli EI (2008) A cryptic promoter in the first exon of the SPG4 gene directs the synthesis of the 60-kDa spastin isoform. BMC Biol 6: 31.
[32]
Canbaz D, K？r？mtay K, Karaca E, Karabay A (2011) SPG4 gene promoter regulation via Elk1 transcription factor. J Neurochem 117: 724–734.
[33]
Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 434: 338–345.
[34]
Lindblad-Toh K, Garber M, Zuk O, Lin MF, Parker BJ, et al. (2011) A high-resolution map of human evolutionary constraint using 29 mammals. Nature 478: 476–482.
[35]
Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, et al. (2009) Diversity and complexity in DNA recognition by transcription factors. Science 324: 1720–1723.
[36]
Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, et al. (2009) Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 69: 709–717.
[37]
Dy P, Penzo-Méndez A, Wang H, Pedraza CE, Macklin WB, et al. (2008) The three SoxC proteins–Sox4, Sox11 and Sox12–exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res 36: 3101–3117.
[38]
Chau CM, Evans MJ, Scarpulla RC (1992) Nuclear respiratory factor 1 activation sites in genes encoding the gamma-subunit of ATP synthase, eukaryotic initiation factor 2 alpha, and tyrosine aminotransferase. Specific interaction of purified NRF-1 with multiple target genes. J Biol Chem 267: 6999–7006.
[39]
Scarpulla RC (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 88: 611–638.
[40]
Fazio IK, Bolger TA, Gill G (2001) Conserved regions of the Drosophila erect wing protein contribute both positively and negatively to transcriptional activity. J Biol Chem 276: 18710–18716.
[41]
Vinson C, Chatterjee R, Fitzgerald P (2011) Transcription factor binding sites and other features in human and Drosophila proximal promoters. Subcell Biochem 52: 205–222.
[42]
Smith KT, Coffee B, Reines D (2004) Occupancy and synergistic activation of the FMR1 promoter by Nrf-1 and Sp1 in vivo. Hum Mol Genet 13: 1611–1621.
[43]
Jing X, Wang T, Huang S, Glorioso JC, Albers KM (2012) The transcription factor Sox11 promotes nerve regeneration through activation of the regeneration-associated gene Sprr1a. Exptl Neurol. 233: 221–232.
[44]
Ramachandran B, Yu G, Gulick T (2008) Nuclear respiratory factor 1 controls myocyte enhancer factor 2A transcription to provide a mechanism for coordinate expression of respiratory chain subunits. J Biol Chem 283: 11935–11946.
[45]
Baek D, Villén J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64–71.
[46]
Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D (2007) MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem 282: 25053–25066.
[47]
Jalvy-Delvaille S, Maurel M, Majo V, Pierre N, Chabas S, et al. (2012) Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res. 40: 1356–1365.
[48]
Lehnert S, Van Loo P, Thilakarathne PJ, Marynen P, Verbeke G, et al. (2009) Evidence for co-evolution between human microRNAs and Alu-repeats. PLoS One 4: e4456.
[49]
Bhattaram P, Penzo-Méndez A, Sock E, Colmenares C, Kaneko KJ, et al. (2010) Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun 1: 9.
[50]
Thein DC, Thalhammer JM, Hartwig AC, Crenshaw EB , Lefebvre V, et al. (2010) The closely related transcription factors Sox4 and Sox11 function as survival factors during spinal cord development. J Neurochem 115: 131–141.
[51]
Lin L, Lee VM, Wang Y, Lin JS, Sock E, et al. (2011) Sox11 regulates survival and axonal growth of embryonic sensory neurons. Dev Dyn 240: 52–64.
[52]
Potzner MR, Tsarovina K, Binder E, Penzo-Méndez A, Lefebvre V, et al. (2010) Sequential requirement of Sox4 and Sox11 during development of the sympathetic nervous system. Development 137: 775–784.
[53]
Stros M, Launholt D, Grasser KD (2007) The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins. Cell Mol Life Sci 64: 2590–2606.
[54]
Gotea V, Visel A, Westlund JM, Nobrega MA, Pennacchio LA, et al. (2010) Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Res 20: 565–577.
[55]
Goodman M, Sterner KN, Islam M, Uddin M, Sherwood CC, et al. (2009) Phylogenomic analyses reveal convergent patterns of adaptive evolution in elephant and human ancestries. Proc Natl Acad Sci USA 106: 20824–20829.
[56]
Kormish JD, Sinner D, Zorn AM (2010) Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn 239: 56–68.
[57]
Xin N, Benchabane H, Tian A, Nguyen K, Klofas L, et al. (2011) Erect Wing facilitates context-dependent Wnt/Wingless signaling by recruiting the cell-specific Armadillo-TCF adaptor Earthbound to chromatin. Development 138: 4955–4967.
[58]
Lu W, Yamamoto V, Ortega B, Baltimore D (2004) Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 119: 97–108.
[59]
Liu Y, Shi J, Lu CC, Wang ZB, Lyuksyutova AI, et al. (2005) Ryk-mediated Wnt repulsion regulates posterior-directed growth of corticospinal tract. Nat Neurosci 8: 1151–1159.
[60]
Li L, Hutchins BI, Kalil K (2009) Wnt5a induces simultaneous cortical axon outgrowth and repulsive axon guidance through distinct signaling mechanisms. J Neurosci 29: 5873–5883.
[61]
David MD, Cantí C, Herreros J (2010) Wnt-3a and Wnt-3 differently stimulate proliferation and neurogenesis of spinal neural precursors and promote neurite outgrowth by canonical signaling. J Neurosci Res 88: 3011–3023.
[62]
Jankowski MP, Cornuet PK, McIlwrath S, Koerber HR, Albers KM (2006) SRY-box containing gene 11 (Sox11) transcription factor is required for neuron survival and neurite growth. Neuroscience 143: 501–514.
[63]
Chang WT, Chen HI, Chiou RJ, Chen CY, Huang AM (2005) A novel function of transcription factor alpha-Pal/NRF-1: increasing neurite outgrowth. Biochem Biophys Res Commun 334: 199–206.
[64]
Butler R, Wood JD, Landers JA, Cunliffe VT (2010) Genetic and chemical modulation of spastin-dependent axon outgrowth in zebrafish embryos indicates a role for impaired microtubule dynamics in hereditary spastic paraplegia. Dis Model Mech 3: 743–751.
[65]
Ciani L, Krylova O, Smalley MJ, Dale TC, Salinas PC (2004) A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol 164: 243–253.
[66]
Kalil K, Li L, Hutchins BI (2011) Signaling mechanisms in cortical axon growth, guidance, and branching. Front Neuroanat 5: 62.
[67]
Yu W, Qiang L, Baas PW (2007) Microtubule-severing in the axon: implications for development, disease, and regeneration after injury. J Environ Biomed 1: 1–7.
[68]
Pierce ML, Weston MD, Fritzsch B, Gabel HW, Ruvkun G, et al. (2008) MicroRNA-183 family conservation and ciliated neurosensory organ expression. Evol Dev 10: 106–113.
[69]
Juhila J, Sipil？ T, Icay K, Nicorici D, Ellonen P, et al. (2011) MicroRNA expression profiling reveals miRNA families regulating specific biological pathways in mouse frontal cortex and hippocampus. PLoS One 6: e21495.
[70]
Wei H, Wang C, Zhang C, Li P, Wang F, et al. (2010) Comparative profiling of microRNA expression between neural stem cells and motor neurons in embryonic spinal cord in rat. Int J Dev Neurosci 28: 545–551.
[71]
Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, et al. (2009) Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 7: e1000238.
Courtine G, Bunge MB, Fawcett JW, Grossman RG, Kaas JH, et al. (2007) Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat Med 13: 561–566.
[74]
Jensen KP, Covault J (2011) Human miR-1271 is a miR-96 paralog with distinct non-conserved brain expression pattern. Nucleic Acids Res 39: 701–711.
[75]
Choi YS, Kim S, Kyu Lee H, Lee KU, Pak YK (2004) In vitro methylation of nuclear respiratory factor-1 binding site suppresses the promoter activity of mitochondrial transcription factor A. Biochem Biophys Res Commun 314: 118–122.
[76]
Lee S, Xu L, Shin Y, Gardner L, Hartzes A, et al. (2011) A potential link between autoimmunity and neurodegeneration in immune-mediated neurological disease. J Neuroimmunol 235: 56–69.
[77]
Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, et al. (2001) Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 281: E1340–E1346.
[78]
Yang SJ, Liang HL, Wong-Riley MT (2006) Activity-dependent transcriptional regulation of nuclear respiratory factor-1 in cultured rat visual cortical neurons. Neurosci 141: 1181–1192.
[79]
Steinberg GR, Kemp BE (2009) AMPK in health and disease. Physiol Rev 89: 1025–1078.
[80]
Beauloye C, Bertrand L, Horman S, Hue L (2011) AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 90: 224–233.
[81]
Dasgupta B, Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104: 7217–7222.
[82]
Yun H, Ha J (2011) AMP-activated protein kinase modulators: a patent review (2006–2010). Expert Opin Ther Pat 21: 983–1005.
[83]
Tarrade A, Fassier C, Courageot S, Charvin D, Vitte J, et al. (2006) A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition. Hum Mol Genet 15: 3544–3558.
[84]
Kasher PR, De Vos KJ, Wharton SB, Manser C, Bennett EJ, et al. (2009) Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients. J Neurochem 110: 34–44.
[85]
Arnold C, Matthews LJ, Nunn CL (2010) The 10kTrees website: A new online resource forprimate phylogeny. Evolut Anthropol 19: 114–118.
[86]
Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16: 869–871.
[87]
Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550–553.
[88]
Stefan M, Portis T, Longnecker R, Nicholls RD (2005) A non-imprinted Prader-Willi syndrome (PWS)-region gene regulates a different chromosomal domain in trans but the imprinted PWS loci do not alter genome-wide mRNA levels. Genomics 85: 630–640.
[89]
Rodriguez-Jato S, Nicholls RD, Driscoll DJ, Yang TP (2005) Characterization of cis- and trans-acting elements in the imprinted human SNURF-SNRPN locus. Nucleic Acids Res 33: 4740–4753.
